ApprovedFDA approval

Hepcludex (bulevirtide-gmod)

Gilead Sciences (GILD)

Marketer take

The first US-approved treatment for chronic hepatitis delta, so hepatologists will need help with HDV testing and diagnosis among hepatitis B patients, where it is often missed.

Sponsor company
Gilead Sciences (GILD)
Indication
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
Therapeutic area
Infectious disease, Hepatology
Event
FDA approval
Date
May 22, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move